Although abnormalities in HER2 occurs in approximately 15% of gastric cancer patients27, activation of its downstream pathways, such as RAS/MEK/MAPK and PI3K/AKT/mTOR, are reported to be more common in gastric cancer tumorigenesis28. Here, MTOR is linked to gastric cancer.